Comparison of a Long-Acting LHRH Agonist and Polyoestradiol Phosphate in the Treatment of Advanced Prostatic Carcinoma

REFERENCES

• Ahmed SR, Brooman PJC, Shalet SM, Howell A, Blacklock NJ, Richards D. Treatment of advanced prostatic cancer with LH-RH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet 1983; 2: 415–418.
   PubMed Web of Science ®Google Scholar
• Aro J. Cardiovascular and all cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 1991; 18: 131–137.
   PubMed Web of Science ®Google Scholar
• Aro J, Haapiainen R, Sane T, Rannikko S, Pelkonen R, Alfthan O. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 1990; 17: 229–235.
   PubMed Web of Science ®Google Scholar
• Beacock CJ, Buck AC, Zwinck R, Peeling WB, Rees RWM, Turkes A, Walker K, Griffiths K. The treatment of metastatic prostatic cancer with the slow release LR-RH analogue Zoladex ICI 118630. Br J Urol 1987; 59: 436–442.
   PubMedGoogle Scholar
• Blackard CE. The Veterans Administration Cooperative Urological Research Group studies of carcinoma of the prostate: A review. Cancer Chemother Res 1975; 59: 225–227.
   PubMedGoogle Scholar
• Chadwick DJ, Gillat DFA, Gingell JC. Medical or surgical orchiectomy: The patient's choice? BMJ 1991; 302: 572.
   PubMedGoogle Scholar
• Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–424.
   PubMed Web of Science ®Google Scholar
• Debruyne FMJ, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 1988; 140: 775–777.
   PubMed Web of Science ®Google Scholar
• De Voogt HJ, Smith PH, Pavone-Macaluso M, De Pauw M, Suiu S, and Members of the European Organization for Research on Treatment of Cancer Urological Group: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of cancer trials 30761 and 30762. J Urol 1986; 136: 303–307.
   PubMedGoogle Scholar
• Fossa SD, Kaasa S, DaSilva FC, Suciu S, Hengeveld MW. Quality of life in prostate cancer patients. Prostate 1992; Suppl 4: 145–148.
   Google Scholar
• Harris AL, Cantwell BMJ. Side-effects of endocrine therapies used to treat breast and prostate cancer. Clin Oncol 1985; 4: 511–533.
   Google Scholar
• Henriksson P, Blombäck M, Erkisson A, Stege R, Carlström K. Effect of parental oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282–285.
   PubMedGoogle Scholar
• Jönsson G. Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol. Scand J Urol Nephrol 1971; 5: 97–102.
   PubMedGoogle Scholar
• Jönsson G, Diczfulasy E, Plantin LO, Röhl L, Birke G. Estradurin® (polyoestradiol phosphate) in the treatment of prostatic carcinoma. A clinical and steroid metabolic study. Acta Endocrinol 1963; Suppl 44: 3–41.
   Google Scholar
• Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502–508.
   PubMedGoogle Scholar
• Lunglmayr G, Girsch E. Patient choice in the treatment of advanced prostate cancer. In: Chisholm GD, ed. International Congress and Symposium Series. London, 1987; 125: 47–51.
   Google Scholar
• Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; Suppl 33: 45–52.
   Google Scholar
• Robinson MRG. Cancer of the prostate: hormone therapy. Clin Oncol 1982; 1: 233–244.
   Google Scholar
• Samdal F, Vada K, Lundmo PI, Mjolnerod OK. Orchidectomy or LHRH analogue? Which do they prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate. Scand J Urol Nephrol 1991; 25: 197–199.
   PubMed Web of Science ®Google Scholar
• Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P. Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology 1985; 26: 117–124.
   PubMed Web of Science ®Google Scholar
• Smith JA, Glode LM, Wettlaufer JN, Stein BS, Glass AG, Max DT, Anbar D, Jagst CL, Murphy GP. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 1985; 254: 106–114.
   Google Scholar
• Soloway MS, Chodak G, Vogelzang NJ, Block NL, Schellhammer PF, Smith JA, Scott M, Kennealey G, Gau TCFor Zoladex Prostate Study Group. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology 1991; 37: 46–51.
   PubMed Web of Science ®Google Scholar
• Veterans Administration Co-operative Urological Research Group (VACURG): Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011–1017.
   PubMedGoogle Scholar
• Thomson IM, Zeidman EJ, Rodriquez FR. Sudden death to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479–1480.
   PubMed Web of Science ®Google Scholar